177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)

被引：0

作者：

Hofman, Michael ^{[1
,2
]}

Emmett, Louise ^{[3
,4
,10
]}

Iravani, Amir ^{[1
,2
]}

Sandhu, Shahneen ^{[1
,2
]}

Joshua, Anthony ^{[3
,4
]}

Pattison, David ^{[5
]}

Goh, Jeffrey ^{[5
]}

Kirkwood, Ian ^{[6
]}

Tan, Thean Hsiang ^{[6
]}

Francis, Roslyn ^{[7
]}

Ng, Siobhan ^{[7
]}

Rutherford, Natalie ^{[8
]}

Gedye, Craig ^{[8
]}

Scott, Andrew ^{[9
]}

Lee, Sze-Ting ^{[9
]}

Weickhardt, Andrew ^{[9
]}

Ramdave, Shakher ^{[10
]}

Kwan, Edmond ^{[10
]}

Azad, Arun ^{[1
]}

Macdonald, William ^{[11
]}

Redfern, Andrew ^{[11
]}

Zhang, Alison ^{[12
]}

Stockler, Martin ^{[13
]}

Martin, Andrew ^{[13
]}

Davis, Ian ^{[14
,15
]}

机构：

[1] Peter MacCalllum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] St Vincents Hosp, Sydney, NSW, Australia

[4] Garvan Inst Med Res, Sydney, NSW, Australia

[5] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia

[6] Royal Adelaide Hosp, Adelaide, SA, Australia

[7] Sir Charles Gairdner Hosp, Perth, WA, Australia

[8] Calvary Mater Newcastle, Newcastle, NSW, Australia

[9] Austin Hlth, Melbourne, Vic, Australia

[10] Monash Hlth, Melbourne, Vic, Australia

[11] Fiona Stanley Hosp, Murdoch, WA, Australia

[12] Australian & New Zealand Urogenital & Prostate Ca, Sydney, NSW, Australia

[13] NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[14] Monash Univ, Melbourne, Vic, Australia

[15] Eastern Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF NUCLEAR MEDICINE | 2021年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

1703

引用

页数：3

共 50 条

[1] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, Michael S.
Emmett, Louise
Sandhu, Shahneen
Iravani, Amir
Joshua, Anthony M.
Goh, Jeffrey C.
Pattison, David A.
Tan, Thean Hsiang
Kirkwood, Ian D.
Ng, Siobhan
Francis, Roslyn J.
Gedye, Craig
Rutherford, Natalie K.
Weickhardt, Andrew
Scott, Andrew M.
Lee, Sze-Ting
Kwan, Edmond M.
Azad, Arun A.
Ramdave, Shakher
Redfern, Andrew D.
Macdonald, William
Guminski, Alex
Hsiao, Edward
Chua, Wei
Lin, Peter
Zhang, Alison Y.
McJannett, Margaret M.
Stockler, Martin R.
Violet, John A.
Williams, Scott G.
Martin, Andrew J.
Davis, Ian D.
LANCET, 2021, 397 (10276): : 797 - 804
[2] Re: [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial
Adeleke, Sola
Haroon, Athar
Kasivisvanathan, Veeru
EUROPEAN UROLOGY, 2021, 80 (01) : 118 - 119
[3] Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, Michael S.
Emmett, Louise
Sandhu, Shahneen
Iravani, Amir
Buteau, James P.
Joshua, Anthony M.
Goh, Jeffrey C.
Pattison, David A.
Tan, Thean Hsiang
Kirkwood, Ian D.
Ng, Siobhan
Francis, Roslyn J.
Gedye, Craig
Rutherford, Natalie K.
Weickhardt, Andrew
Scott, Andrew M.
Lee, Sze-Ting
Kwan, Edmond M.
Azad, Arun A.
Ramdave, Shakher
Redfern, Andrew
Macdonald, William
Guminski, Alex
Hsiao, Edward
Chua, Wei
Lin, Peter
Zhang, Alison Yan
Stockler, Martin R.
Williams, Scott G.
Martin, Andrew J.
Davis, Ian D.
LANCET ONCOLOGY, 2024, 25 (01): : 99 - 107
[4] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
Radtke, Jan Philipp
Albers, Peter
Giesel, Frederik Lars
AKTUELLE UROLOGIE, 2022, 53 (02)
[5] TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer
Hofman, Michael
Emmett, Louise
Violet, John A.
Lawrence, Nicola Jane
Williams, Scott
Stockler, Martin R.
Francis, Roslyn J.
Iravani, Amir
Zhang, Alison Yan
Martin, Andrew James
Azad, Arun
Yip, Sonia
Langford, Ailsa
McJannett, Margaret Mary
Davis, Ian D.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[6] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
Rohith, Gorrepati
INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
[7] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial
Buteau, James P.
Martin, Andrew J.
Emmett, Louise
Iravani, Amir
Sandhu, Shahneen
Joshua, Anthony M.
Francis, Roslyn J.
Zhang, Alison Y.
Scott, Andrew M.
Lee, Sze-Ting
Azad, Arun A.
McJannett, Margaret M.
Stockler, Martin R.
Williams, Scott G.
Davis, Ian
Hofman, Michael S.
LANCET ONCOLOGY, 2022, 23 (11): : 1389 - 1397
[8] TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Hofman, Michael S.
Emmett, Louise
Violet, John
Zhang, Alison Y.
Lawrence, Nicola J.
Stockler, Martin
Francis, Roslyn J.
Iravani, Amir
Williams, Scott
Azad, Arun
Martin, Andrew
McJannett, Margaret
Davis, Ian D.
BJU INTERNATIONAL, 2019, 124 : 5 - 13
[9] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
Qu, Gengcuo
Hua, Qingchu
Li, Hongmei
Zhang, Yu
Chen, Yue
CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
[10] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Sun, Michael
Niaz, Muhammad O.
Nelson, Adlai
Skafida, Myrto
Niaz, Muhammad J.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)

← 1 2 3 4 5 →